Daiichi Sankyo Co., Ltd. (DSNKY)

Quick facts

Marketed products

• Enhertu · Oncology · revenue 2900
  Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells.
• Savaysa · Cardiovascular · revenue 1800
  Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting.
• Tarlige · Metabolic · revenue 300
• colesevelam HCl tablets and fenofibrate tablets
• Datroway · Oncology
  Deruxtecan works by binding to and inhibiting the growth of cancer cells.
• Minnebro · Metabolic
• hydrochlorothiazide tablets
• Hydroclorothiazide · Other
• Inavir · Infectious Disease
• Low-dose colesevelam
• Vanflyta · Oncology
  Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells.
• Gracevit · Infectious Disease
• TURALIO™ · Oncology
  Turalio works by inhibiting a specific biological pathway.
• Ezharmia · Oncology
• Welchol · Metabolic

Phase 2 pipeline

• Mevalotin · Other

Phase 1 pipeline

• 14C-Quizartinib solution for infusion
• Buproprion · Other
• DS-3201b

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Daiichi Sankyo Co., Ltd. portfolio CI brief
• Daiichi Sankyo Co., Ltd. pipeline updates RSS